Moderna and Merck Report 5-Year Data for Melanoma Cancer Vaccine Intismeran Autogene
Dec 09, 2025
Moderna and Merck announced median five-year follow-up data showing intismeran autogene in combination with Keytruda reduced the risk of melanoma recurrence or death by 49% in high-risk patients following complete resection.